The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

• Status: Active, not recruiting
• Trial end date: 2033-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First People's Hospital of Changzhou
• Treatments: Apatinib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed Lung adenocarcinoma

• Wld-type EGFR

• Stage IIIB/IV

• Failure to prior chemotherapy

• Life expectancy of more than 3 months

• Tissue sample desired for genomic study

• Age ≥ 18 years

• Performance status (WHO) < 3

• Adequate bone marrow function (absolute neutrophil count>1000/mm^3, platelet count > 100000/mm^3, hemoglobin > 9gr/mm^3)

• Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times upper limit of normal) and renal function (creatinine < 2mg/dl)

• Presence of two-dimensional measurable disease. The measurable disease should not have been irradiated

• Informed consent

Exclusion Criteria:

• Lung squamous cell carcinoma or other types of Non-Small cell lung cancer

• Small cell lung cancer

• Have previously received TKIs

• Hemoglobin<8.0 g/dL,White blood cell <3 X 10^9/L;Platelet count <75 X 10^9/L; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times

• Known or suspected allergy to the investigational agent or any agent given in association with this trial

• Pregnant or lactating patients

• Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection

• Patients who are suffering from serious autoimmune disease

• Patients who had used long time or are using immunosuppressant

• Patients who had active infection

• Patients who are suffering from serious organ dysfunction

• Patients who are suffering from other cancer

• Other situations that the researchers considered unsuitable for this study.

• Other concurrent uncontrolled illness